Artery Research

Volume 26, Issue 3, September 2020, Pages 137 - 142

Monoclonal Antibodies in Oncology and their Effect on Arterial Stiffness – A Systematic Review

Authors
Eirini Solomou, Konstantinos Aznaouridis, Dimitrios Terentes-Printzios, Maria Drakopoulou, Konstantinos Toutouzas, Dimitris Tousoulis, Charalambos Vlachopoulos*
1st Department of Cardiology, Hippokration Hospital, Athens, Greece
*Corresponding author. Email: cvlachop@otenet.com
Corresponding Author
Charalambos Vlachopoulos
Received 31 December 2019, Accepted 15 February 2020, Available Online 18 April 2020.
DOI
10.2991/artres.k.200323.001How to use a DOI?
Keywords
Monoclonal antibodies; anticancer treatment; cardiotoxicity; arterial stiffness; arterial inflammation; pulse wave velocity
Abstract

Introduction: Malignancies are the second leading cause of death worldwide. Treatment Monoclonal Antibody (MAbs)-based treatment of cancer has been established as one of the most successful therapeutic strategies in the last 20 years; however, there is a growing concern about the effects of these agents on patients’ cardiovascular profile.

Areas Covered: In this manuscript we summarize current evidence regarding MAb effects on arterial stiffness, which is an recognised biomarker of cardiovascular risk. For this purpose, we explored two bibliographic databases [PubMed, Scopus] and one full-text database (Google-Scholar) for all publications published on MAbs’ effects on arterial stiffness until December 2019. Only few of the monoclonal antibody agents used in oncology have been investigated as per their effects on arterial properties and this limited evidence suggests that cancer therapy with monoclonal antibodies demonstrates either a temporary or long-term increase in arterial stiffness.

Discussion: It seems that by targeting ‘checkpoints’ in cancer genesis, anticancer MAbs also affects vascular properties causing endothelial dysfunction and arterial stiffness. Furthermore, several MAbs cause hypertension and may as a result increase pulse wave velocity. On the other hand, MAbs that target inflammatory cytokines seem to improve cardiovascular survival however, their effect on arterial stiffness is yet to be investigated. Further research is warranted in order to elucidate the biochemical pathways, clinical implications and potential reversibility of monoclonal antibody chemotherapy-induced vascular dysfunction.

Copyright
© 2020 Association for Research into Arterial Structure and Physiology. Publishing services by Atlantis Press International B.V.
Open Access
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Download article (PDF)
View full text (HTML)

Journal
Artery Research
Volume-Issue
26 - 3
Pages
137 - 142
Publication Date
2020/04/18
ISSN (Online)
1876-4401
ISSN (Print)
1872-9312
DOI
10.2991/artres.k.200323.001How to use a DOI?
Copyright
© 2020 Association for Research into Arterial Structure and Physiology. Publishing services by Atlantis Press International B.V.
Open Access
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Cite this article

TY  - JOUR
AU  - Eirini Solomou
AU  - Konstantinos Aznaouridis
AU  - Dimitrios Terentes-Printzios
AU  - Maria Drakopoulou
AU  - Konstantinos Toutouzas
AU  - Dimitris Tousoulis
AU  - Charalambos Vlachopoulos
PY  - 2020
DA  - 2020/04/18
TI  - Monoclonal Antibodies in Oncology and their Effect on Arterial Stiffness – A Systematic Review
JO  - Artery Research
SP  - 137
EP  - 142
VL  - 26
IS  - 3
SN  - 1876-4401
UR  - https://doi.org/10.2991/artres.k.200323.001
DO  - 10.2991/artres.k.200323.001
ID  - Solomou2020
ER  -